A statement issued 2 years ago to that newly forming cancer company, (GCT) from IBX's CEO...
“Our proprietary technologies and methods employ magnetic nanoparticles targeted toward cells associated with cancer and other diseases and provide the ability to detect these cells using highly sensitive magnetic sensors. We are in collaboration with Global Cancer Technology and their scientists to explore their very promising drug delivery technology. We envision a nanotechnology platform that would deliver both our proprietary imaging capabilities along with the targeted therapeutic capabilities that GCT provides. With a successful collaboration physicians, for the first time, would be able to image and treat a tumor using a single nanotechnology delivery medium.”
Robert Prouix
President & CEO, Imagion Biosystems Inc
IBX Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
